accession	classification	samplingFrame	paper	length
AY184220	Sabin2	Sabin 2	Mutations in Sabin 2 strain of poliovirus and stability ofattenuation phenotype 	1725
KC784368	VDPV	environmental	Highly Divergent Types 2 and 3 Vaccine-Derived PoliovirusesIsolated from Sewage in Tallinn, Estonia 	1725
KX162717	SabinLike	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162716	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162715	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162714	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162713	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162712	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162711	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162710	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162707	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162706	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162705	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162704	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162703	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162702	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162701	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162700	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162699	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162698	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162697	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162696	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162690	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162689	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162688	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162687	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162686	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162685	SabinLike	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KX162678	cVDPV	AFP	High-Throughput Next Generation Sequencing of Polioviruses	1725
KJ170575	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170574	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170573	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170572	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170571	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170570	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170569	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170568	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170567	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170566	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170565	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170564	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170563	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170562	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170561	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170560	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170559	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170558	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170557	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170556	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170555	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170554	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170553	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170552	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170551	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170550	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170549	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170548	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170547	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170546	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170545	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170544	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170543	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170542	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170541	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170540	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170539	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170538	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170537	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170536	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170535	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170534	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KJ170533	SabinLike	AFP	Sabin Vaccine Reversion in the Field: a Comprehensive Analysis ofSabin-Like Poliovirus Isolates in Nigeria 	1725
KU598891	VDPV	AFP	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598890	VDPV	healthy	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598889	VDPV	healthy	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598888	VDPV	AFP	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598887	VDPV	AFP	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598886	VDPV	AFP	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598885	VDPV	AFP	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598884	VDPV	AFP	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU598883	VDPV	AFP	A cluster of paralytic poliomyelitis cases due to transmission ofslightly diverged Sabin-2 vaccine virus 	1725
KU372652	VDPV	environmental	Molecular and Phenotypic Characterization of a Highly Evolved Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014	1725
KM433732	SabinLike	AFP-CSF	Complete genome sequence analysis of a poliovirus type 2 strainisolated in Yunnan, China, in 2013 	1725
KR259357	VDPV	AFP	Vaccine-Derived Polioviruses Not Detected by Global SurveillanceScreening Assay 	1725
KR259356	VDPV	AFP	Vaccine-Derived Polioviruses Not Detected by Global SurveillanceScreening Assay 	1725
KP196613	VDPV	AFP	The Genetic Character Analysis of Type 2 Vaccine-derived Poliovirusin Shanxi Province in 2014 	1725
KJ419277	cVDPV	healthy	Limited and localized outbreak of newly emergent type 2vaccine-derived poliovirus in sichuan, china 	1725
KJ419276	cVDPV	AFP	Limited and localized outbreak of newly emergent type 2vaccine-derived poliovirus in sichuan, china 	1725
KJ419275	cVDPV	AFP	Limited and localized outbreak of newly emergent type 2vaccine-derived poliovirus in sichuan, china 	1725
KJ419274	cVDPV	AFP	Limited and localized outbreak of newly emergent type 2vaccine-derived poliovirus in sichuan, china 	1725
KJ419273	cVDPV	AFP	Limited and localized outbreak of newly emergent type 2vaccine-derived poliovirus in sichuan, china 	1725
KF656732	VDPV	environmental	Isolation and Characterization of a Type 2 Vaccine-DerivedPoliovirus from Environmental Surveillance in China, 2012 	1725
KC784367	VDPV	environmental	Highly Divergent Types 2 and 3 Vaccine-Derived PoliovirusesIsolated from Sewage in Tallinn, Estonia 	1725
HF913428	VDPV	healthy	Reemergence of Recombinant Vaccine-derived Polioviruses in HealthyChildren, Madagascar 	1725
HF913427	VDPV	healthy	Reemergence of Recombinant Vaccine-derived Polioviruses in HealthyChildren, Madagascar 	1725
HF913426	VDPV	healthy	Reemergence of Recombinant Vaccine-derived Polioviruses in HealthyChildren, Madagascar 	1725
JX275380	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275352	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275266	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275238	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275184	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275162	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275147	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275140	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275085	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275071	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275032	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275015	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX275008	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274999	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274995	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274993	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274991	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274987	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274985	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274984	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274983	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274982	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274981	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
JX274980	cVDPV	AFP	Multiple Independent Emergences of Type 2 Vaccine-DerivedPolioviruses during a Large Outbreak in Northern Nigeria 	1725
AY278552	VDPV	healthy	Retrospective analysis of a local cessation of vaccination againstpoliomyelitis: a possible scenario for the future 	1725
AY278551	VDPV	AFP	Retrospective analysis of a local cessation of vaccination againstpoliomyelitis: a possible scenario for the future 	1725
AY278550	VDPV	healthy	Retrospective analysis of a local cessation of vaccination againstpoliomyelitis: a possible scenario for the future 	1725
AY278549	VDPV	healthy	Retrospective analysis of a local cessation of vaccination againstpoliomyelitis: a possible scenario for the future 	1725
GU390707	iVDPV	AFP	Brief Report: Neuroinvasive Immunodeficiency-Associated Vaccine-Derived Poliomyelitis Thirteen Years after Infection -Minnesota, 2008 	1725
HM107835	SabinLike	AFP	Type 2 vaccine-derived poliovirus from patients with acute flaccidparalysis in china: current immunization strategy effectively prevented its sustained transmission 	1725
HM107834	VDPV	AFP	Type 2 vaccine-derived poliovirus from patients with acute flaccidparalysis in china: current immunization strategy effectively prevented its sustained transmission 	1725
HM107833	VDPV	AFP	Type 2 vaccine-derived poliovirus from patients with acute flaccidparalysis in china: current immunization strategy effectively prevented its sustained transmission 	1725
HM107832	VDPV	AFP	Type 2 vaccine-derived poliovirus from patients with acute flaccidparalysis in china: current immunization strategy effectively prevented its sustained transmission 	1725
AY177685	iVDPV	AFP	Nucleotide variation in Sabin type 2 poliovirus from animmunodeficient patient with poliomyelitis 	1725
FJ460225	VDPV	healthy	Comparison of poliovirus recombinants: accumulation of pointmutations provides further advantages 	1725
FJ460224	VDPV	healthy	Comparison of poliovirus recombinants: accumulation of pointmutations provides further advantages 	1725
FJ460223	VDPV	healthy	Comparison of poliovirus recombinants: accumulation of pointmutations provides further advantages 	1725
FJ517649	VDPV	AFP	Evolution of the Sabin vaccine into pathogenic derivatives withoutappreciable changes in antigenic properties: need for improvement of current poliovirus surveillance 	1725
FJ517648	VDPV	AFP	Evolution of the Sabin vaccine into pathogenic derivatives withoutappreciable changes in antigenic properties: need for improvement of current poliovirus surveillance 	1725
EU566950	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566949	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566948	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566947	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566946	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566945	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566944	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566943	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566942	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566941	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566940	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566939	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566938	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566937	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566936	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566935	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
EU566934	iVDPV	AFP	Paralysis Associated and Contact Spreading of an ImportedRecombinant Vaccine Derived Poliovirus in Spain 	1725
DQ890388	VDPV	AFP	Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV)from a Nigerian child 	1725
DQ890387	VDPV	AFP	Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV)from a Nigerian child 	1725
DQ890386	VDPV	AFP	Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV)from a Nigerian child 	1725
DQ890385	VDPV	AFP	Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV)from a Nigerian child 	1725
AF448783	cVDPV	AFP	Circulation of endemic type 2 vaccine-derived poliovirus in Egyptfrom 1983 to 1993 	1725
AF448782	cVDPV	AFP	Circulation of endemic type 2 vaccine-derived poliovirus in Egyptfrom 1983 to 1993 	1725
FJ898290	VDPV	AFP	A Sabin 2-related poliovirus recombinant contains a homologous sequence of human enterovirus species C in the viral polymerasecoding region 	1725
AY948201	VDPV	AFP	Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a childwith acute flaccid paralysis 	1725
DQ205099	engineered	engineered	Modulation of Poliovirus Replicative Fitness in HeLa Cells byDeoptimization of Synonymous Codon Usage in the Capsid Region	1725
AY238473	MEF1	MEF1	Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method forpredicting vaccine efficacy 	1725
AM084225	cVDPV	AFP	Co-circulation and evolution of polioviruses and species Centeroviruses in a district of Madagascar 	1725
AM084224	cVDPV	AFP	Co-circulation and evolution of polioviruses and species Centeroviruses in a district of Madagascar 	1725
AM084223	cVDPV	AFP	Co-circulation and evolution of polioviruses and species Centeroviruses in a district of Madagascar 	1725
AM884185	cVDPV	healthy	Co-circulation and evolution of polioviruses and species Centeroviruses in a district of Madagascar 	1725
AM884184	cVDPV	healthy	Co-circulation and evolution of polioviruses and species Centeroviruses in a district of Madagascar 	1725
AM040039	VDPV	environmental	Neurovirulent vaccine-derived polioviruses in sewage from highlyimmune populations 	1725
AM040038	VDPV	environmental	Neurovirulent vaccine-derived polioviruses in sewage from highlyimmune populations 	1725
AM040037	VDPV	environmental	Neurovirulent vaccine-derived polioviruses in sewage from highlyimmune populations 	1725
AM040036	VDPV	environmental	Neurovirulent vaccine-derived polioviruses in sewage from highlyimmune populations 	1725
AM040035	VDPV	environmental	Neurovirulent vaccine-derived polioviruses in sewage from highlyimmune populations 	1725
AJ544513	iVDPV	healthy	Characterisation of a type 2 poliovirus strain from long-termexcretor with CVID immunodeficiency 	1725
CS406483	engineered	engineered	Modulation of replicative fitness by using less frequently usedsynonymous codons 	1725
CS406482	engineered	engineered	Modulation of replicative fitness by using less frequently usedsynonymous codons 	1725
CS406436	engineered	engineered	Modulation of replicative fitness by using less frequently usedsynonymous codons 	1725
M12197	Lansing	Lansing	Mapping of sequences required for mouse neurovirulence ofpoliovirus type 2 Lansing 	1725
EU598488	VDPV	AFP	Growth kinetic analysis of bi-recombinant poliovirus vaccinestrains 	1720
EU598486	VDPV	environmental	A new RT-PCR assay for the identification of the predominant recombination types in 2C and 3D genomic regions of vaccine-derivedpoliovirus strains 	1720
JN812706	wild	AFP	Phylogenetic study of wild poliovirus that circulated inpre-eradication era in Brazil 	987
JN812693	wild	AFP	Phylogenetic study of wild poliovirus that circulated inpre-eradication era in Brazil 	987
JN812675	wild	AFP	Phylogenetic study of wild poliovirus that circulated inpre-eradication era in Brazil 	987
JN812674	wild	AFP	Phylogenetic study of wild poliovirus that circulated inpre-eradication era in Brazil 	987
AY820974	VDPV	AFP	Vaccine derived bi- and multi-recombinant Sabin strains	943
AY820972	VDPV	environmental	Recombinant Sabin environmental isolates in Greece and Cyprus	942
AY736179	VDPV	unknown	Genomic analysis of recombinant sabin clinical isolates	939
AY820975	VDPV	AFP	Vaccine derived bi- and multi-recombinant Sabin strains	936
AY738635	VDPV	AFP	Vaccine derived bi- and multi-recombinant Sabin strains	936
AY738636	VDPV	AFP	Vaccine derived bi- and multi-recombinant Sabin strains	935
EU715814	VDPV	unknown	Determination of the role of mutations and recombination in growthrates of Poliovirus vaccine strains 	934
AY820973	VDPV	environmental	Recombinant Sabin environmental isolates in Greece and Cyprus	934
AY820971	VDPV	environmental	Recombinant Sabin environmental isolates in Greece and Cyprus	929
AY820970	VDPV	environmental	Recombinant Sabin environmental isolates in Greece and Cyprus	929
AY738637	VDPV	AFP	Vaccine derived bi- and multi-recombinant Sabin strains	929
AY736177	VDPV	unknown	Genomic analysis of recombinant sabin clinical isolates	929
AY736180	VDPV	unknown	Genomic analysis of recombinant sabin clinical isolates	901
